|
Market Closed -
Euronext Paris
09:25:00 15/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 21.40 EUR | -1.74% |
|
-5.31% | -15.08% |
| 02/09 | Medincell Names Chief Medical Officer | MT |
| 02/09 | Medincell Announces Appointment of Edna Venneker as Chief Medical Officer | CI |
| Market Cap | 77Cr 89Cr 73Cr 66Cr 123.48Cr 8.51TCr 124.41Cr 867.21Cr 333.64Cr 4.32TCr 333.27Cr 325.88Cr 14TCr | P/E 2027 * |
357x | P/E 2028 * | 45x |
|---|---|---|---|---|---|
| Enterprise Value | 75Cr 87Cr 71Cr 65Cr 121.09Cr 8.35TCr 122Cr 850.43Cr 327.18Cr 4.23TCr 326.82Cr 319.57Cr 13TCr | EV / Sales 2027 * |
17.1x | EV / Sales 2028 * | 12.5x |
| Free-Float |
66.06% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| MEDCL | Real-time | |
London S.E.
| 0ACH | Delayed | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| MEB | Real-time | |
|
Börse Stuttgart
| MEB | Delayed | |
|
Tradegate
| MEB | Real-time | |
|
Deutsche Boerse AG
| MEB | Delayed | |
|
CBOE
| 0ACH | Real-time |
Last Transcript: MedinCell S.A.
| 1 day | -1.74% | ||
| 1 week | -5.31% | ||
| Current month | -11.72% | ||
| 1 month | -11.20% | ||
| 3 months | -23.08% | ||
| 6 months | +5.21% | ||
| Current year | -15.08% |
| 1 week | 21.16 |  | 22.42 |
| 1 month | 21.16 | | 25.28 |
| Current year | 19.69 | | 29.76 |
| 1 year | 19.46 | | 39.68 |
| 3 years | 5.25 | | 39.68 |
| 5 years | 4.73 | | 39.68 |
| 10 years | 4.35 | | 39.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 62 | 09/01/2003 |
Stéphane Postic
DFI | Director of Finance/CFO | 52 | 01/09/2023 |
Edna Venneker
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Christophe Douat
BRD | Director/Board Member | 62 | 09/01/2003 |
Philippe Guy
CHM | Chairman | - | 13/03/2024 |
Virginie Lleu
BRD | Director/Board Member | - | 25/05/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 26/02/25 | Buy | General Counsel | 2,943 | 0.0099% | ||
| 21/02/25 | Buy | Chief Financial Officer | 3,749 | 0.0126% | ||
| 06/05/23 | Sell | Founder | 60,000 | 0.2376% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.74% | -5.31% | +6.15% | +214.71% | 90Cr | |
| -0.19% | +1.09% | +51.85% | +97.36% | 1,01500Cr | |
| +0.33% | -0.71% | +50.62% | +65.50% | 64TCr | |
| +0.49% | +5.73% | +20.88% | +72.92% | 46TCr | |
| -0.22% | +2.88% | +38.48% | +37.98% | 35TCr | |
| -0.07% | +1.82% | +16.57% | +23.39% | 26TCr | |
| -0.31% | +2.02% | +6.15% | +10.75% | 25TCr | |
| -1.53% | -4.46% | +36.90% | +44.08% | 21TCr | |
| -1.60% | -5.51% | -22.30% | -58.60% | 19TCr | |
| +0.49% | -0.23% | +30.00% | +93.34% | 18TCr | |
| Average | -0.25% | -1.51% | +23.53% | +60.14% | 35.71TCr | |
| Weighted average by Cap. | +0.40% | +0.00% | +34.46% | +59.33% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4.41Cr 5.1Cr 4.17Cr 3.78Cr 7.09Cr 488.85Cr 7.15Cr 50Cr 19Cr 247.87Cr 19Cr 19Cr 790.5Cr | 5.89Cr 6.8Cr 5.57Cr 5.04Cr 9.47Cr 652.51Cr 9.54Cr 66Cr 26Cr 330.86Cr 26Cr 25Cr 1.06TCr |
| Net income | 7L 8L 6L 6L 10.71L 7.38Cr 10.79L 75.23L 28.94L 3.74Cr 28.91L 28.27L 12Cr | 1.33Cr 1.54Cr 1.26Cr 1.14Cr 2.14Cr 147.58Cr 2.16Cr 15Cr 5.79Cr 75Cr 5.78Cr 5.65Cr 238.65Cr |
| Net Debt | -1.49Cr -1.72Cr -1.41Cr -1.27Cr -2.39Cr -164.64Cr -2.41Cr -17Cr -6.45Cr -83Cr -6.45Cr -6.3Cr -266.23Cr | -3.05Cr -3.52Cr -2.89Cr -2.61Cr -4.91Cr -338.13Cr -4.94Cr -34Cr -13Cr -171.45Cr -13Cr -13Cr -546.79Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | €21.40 | -1.74% | 62,399 |
| 14/26/14 | €21.78 | +0.09% | 1,30,795 |
| 11/26/11 | €21.76 | -0.18% | 76,652 |
| 10/26/10 | €21.80 | -1.00% | 90,306 |
| 09/26/09 | €22.02 | -2.57% | 74,398 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MEDCL Stock
Select your edition
All financial news and data tailored to specific country editions
